Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511898 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
A Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT03511898 is a Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema that has completed, run by ThromboGenics. The registered enrollment target is 12 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT03511898, a Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
Conditions Studied
Interventions
- DRUG THR-149 dose level 1
- DRUG THR-149 dose level 2
- DRUG THR-149 dose level 3
Study Locations (7)
Texas
- Retina Research Institute of Texas - Abilene
- Retinal Research Center, PLLC - Austin
- Retina Consultants of Houston - Houston
Arizona
- Retina Consultants of Arizona - Phoenix
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Nevada
- Sierra Eye Associates - Reno
Pennsylvania
- Mid Atlantic Retina - Huntingdon Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511898
The ClinicalTrials.gov registry entry for NCT03511898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which THR-149 dose level 1 is the first listed.
NCT03511898 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Texas, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03511898 about?
NCT03511898 is a clinical study titled "A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)". This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
What is the current status of trial NCT03511898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-05-18. Estimated completion is 2019-05-22.
What conditions does trial NCT03511898 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT03511898?
The interventions under investigation include: THR-149 dose level 1 (DRUG), THR-149 dose level 2 (DRUG), THR-149 dose level 3 (DRUG).
Who is sponsoring clinical trial NCT03511898?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511898 being conducted?
This trial has 7 study locations across Arizona, Massachusetts, Nevada, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
RECRUITING · Phase 1
-
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
-
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
COMPLETED · Phase 1
-
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.